SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Zenflow, Inc., developer of the Zenflow Spring® System, announced the close of an oversubscribed $52 million Series D financing round. The round was led by Cook Medical, with participation from new investor ClavystBio, as well as existing investors Invus Opportunities, F-Prime, Medtech Venture Partners, and others. The round was further supported with venture debt financing from HSBC Bank USA, N.A. and Trinity Capital. Proceeds from this financing will accelerate the company’s commercial launch following PMA approval from the U.S. Food and Drug Administration of the Zenflow Spring® System, achieved in December 2025.
The Zenflow Spring is the first and only product to offer simple, in-office treatment for benign prostatic hyperplasia (BPH), with sizing options and full reversibility if desired. For the more than 30 million U.S. men living with BPH (also known as an enlarged prostate) Spring treatment opens a new category of treatment called first-line interventional therapy (FIT), giving physicians a device-based option they can offer instead of drug therapy thanks to the long-term durability and safety advantages, including no post-procedure catheter, and preservation of sexual function.
In addition to the financing, Zenflow announced it has entered into an exclusive U.S. distribution agreement with Cook Medical, a leading medical device company with a proven track record in urology.